In recent years, immunotherapy targeting PD-1/PD-L1 has achieved encouraging therapeutic effects in diverse cancers, and NCCN guidelines recommend pembrolizumab as a choice for advanced cholangiocarcinoma with dMMR or MSI-H [13–16]. Here, PDCD1 is linked to cholangiocarcinoma.